Fox Run Management L.L.C. Invests $80,000 in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Fox Run Management L.L.C. acquired a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the fourth quarter, Holdings Channel reports. The firm acquired 13,769 shares of the company’s stock, valued at approximately $80,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in OLMA. KLP Kapitalforvaltning AS acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at $30,000. Teacher Retirement System of Texas acquired a new position in Olema Pharmaceuticals during the fourth quarter worth about $60,000. Monaco Asset Management SAM acquired a new stake in Olema Pharmaceuticals in the 4th quarter valued at about $146,000. HighTower Advisors LLC acquired a new stake in Olema Pharmaceuticals in the 4th quarter valued at about $510,000. Finally, AlphaQuest LLC boosted its position in shares of Olema Pharmaceuticals by 867.6% during the 4th quarter. AlphaQuest LLC now owns 18,414 shares of the company’s stock valued at $107,000 after purchasing an additional 16,511 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Oppenheimer reissued an “outperform” rating and set a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase & Co. cut their target price on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

Insider Transactions at Olema Pharmaceuticals

In other news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the stock in a transaction on Wednesday, January 8th. The shares were purchased at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the purchase, the insider now directly owns 7,800,000 shares of the company’s stock, valued at $44,928,000. This trade represents a 4.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.40% of the stock is owned by insiders.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $4.11 on Friday. The firm’s 50 day moving average price is $4.98 and its two-hundred day moving average price is $8.08. The stock has a market cap of $280.85 million, a price-to-earnings ratio of -1.88 and a beta of 2.11. Olema Pharmaceuticals, Inc. has a twelve month low of $3.93 and a twelve month high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.12. On average, research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.